Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial

• DOI: 10.1186/s12905-017-0446-3
• Publication Date: 2017-09-26T08:11:30Z
• Authors: Wanwisa Waiyaput; Somphoch Pumipichet; Sawaek Weerakiet; Sasivimol Rattana...; Areepan Sophonsri...
• Keywords: CD68; Monocyte

Simvastatin is a promising new drug for the treatment of endometriosis. It cholesterol-lowering that acts by inhibiting HMG-CoA reductase, resulting in decrease mevalonate, precursor cholesterol and monocyte chemoattractant protein-1 (MCP-1). This study investigated effect pre-operative oral simvastatin administration on MCP-1 gene expression serum protein levels patients with A prospective, randomized, controlled was conducted at Reproductive Endocrinology Unit Department Obstetrics Gynecology Faculty Medicine Ramathibodi Hospital. Forty women (mean age: 18–45 years) scheduled laparoscopic surgery who had been diagnosed endometriosis were recruited randomly assigned to either group (20 mg/d orally administered 2 weeks before surgery) or an untreated control group. Serum collected after determined. CD68 transcript also quantified using real-time PCR endometriotic cyst tissues. not significantly different between simvastatin-treated groups (P = 0.99). higher compared group, but this statistically significant 0.055). following than samples obtained (297.89 ± 70.77 255.51 63.79 pg/ml, respectively) 0.01). Treatment 20 did reduce chemokine macrophage-specific genes. Cumulatively, suggests ideal treating because dose (40–100 mg/d) would be needed achieve target outcome, which increase risk myopathy patients. Thai Clinical Trials Registry TCTR20130627003 Registered: June 27, 2013.